Journal
ACTA PHARMACOLOGICA SINICA
Volume 26, Issue 1, Pages 1-9Publisher
NATURE PUBLISHING GROUP
DOI: 10.1111/j.1745-7254.2005.00008.x
Keywords
antibody engineering; bispecific antibody; diabodies; single-chain diabodies; tandem scFv; targeting; effector cells; cancer therapy
Ask authors/readers for more resources
Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available